Cargando…

Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials

BACKGROUND: Prediction models for venous thromboembolism recurrence will likely be improved by adding levels of coagulation factors. Risk assessment is ideally performed during anticoagulant treatment, however, the influence of direct oral anticoagulants on coagulation factors is uncertain. OBJECTIV...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scheres, Luuk J. J., Lijfering, Willem M., Middeldorp, Saskia, Cheung, Yuk W., Barco, Stefano, Cannegieter, Suzanne C., Coppens, Michiel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles: Thrombosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178718/ https://www.ncbi.nlm.nih.gov/pubmed/30349888 http://dx.doi.org/10.1002/rth2.12142

Ejemplares similares

Effect of gender‐affirming hormone use on coagulation profiles in transmen and transwomen
por: Scheres, Luuk J.J., et al.
Publicado: (2021)

Predicting the risk of recurrent venous thrombosis: What the future might bring
por: Lijfering, Willem M., et al.
Publicado: (2019)

Risk prediction of recurrent venous thrombosis; where are we now and what can we add?
por: Timp, Jasmijn F., et al.
Publicado: (2019)

Sex‐specific differences in clot resolution 3 weeks after acute pulmonary embolism managed with anticoagulants—A substudy of the EINSTEIN‐PE study
por: Wiegers, Hanke M. G., et al.
Publicado: (2021)

Bloodcurdling movies and measures of coagulation: Fear Factor crossover trial
por: Nemeth, Banne, et al.
Publicado: (2015)

Procoagulant factors and future risk of arterial cardiovascular disease in patients with prior venous thrombosis: A cohort study
por: Yap, Eng Soo, et al.
Publicado: (2023)

Risk of recurrence in women with venous thromboembolism related to estrogen‐containing contraceptives: Systematic review and meta‐analysis
por: Wiegers, Hanke M. G., et al.
Publicado: (2022)

Endogenous sex hormones and risk of venous thromboembolism in young women
por: Scheres, Luuk J. J., et al.
Publicado: (2019)

Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns
por: Toorop, Myrthe M. A., et al.
Publicado: (2020)

Current and future burden of venous thrombosis: Not simply predictable
por: Scheres, Luuk J. J., et al.
Publicado: (2018)

The joint effect of genetic risk factors and different types of combined oral contraceptives on venous thrombosis risk
por: Khialani, Deeksha, et al.
Publicado: (2020)

Clinical outcome of patients with a vitamin K antagonist‐associated bleeding treated with prothrombin complex concentrate
por: Brekelmans, Marjolein P. A., et al.
Publicado: (2017)

Glucocorticoid use and risk of first and recurrent venous thromboembolism: self‐controlled case‐series and cohort study
por: Orsi, Fernanda A., et al.
Publicado: (2021)

Glucose levels and diabetes are not associated with the risk of venous thrombosis: results from the MEGA case‐control study
por: Li‐Gao, Ruifang, et al.
Publicado: (2018)

A universal anti‐Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation
por: Willekens, Guido, et al.
Publicado: (2021)

Hypertensive Complications of Pregnancy and Risk of Venous Thromboembolism
por: Scheres, Luuk J.J., et al.
Publicado: (2020)

Assessment of the effect of direct oral anticoagulants dabigatran, rivaroxaban, and apixaban in healthy male volunteers using a thrombin generation assay
por: Artang, Ramin, et al.
Publicado: (2017)

Growth differentiation factor‐15 for prediction of bleeding in cancer patients
por: Mulder, Frits I., et al.
Publicado: (2021)

Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older
por: Ageno, Walter, et al.
Publicado: (2021)

Lower-leg injury and knee arthroscopy have distinct effects on coagulation
por: Touw, Carolina E., et al.
Publicado: (2022)

Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation
por: Kim, Paul Y., et al.
Publicado: (2018)

Guidance on the critical shortage of sodium citrate coagulation tubes for hemostasis testing
por: Gosselin, Robert C., et al.
Publicado: (2021)

Factor V levels and risk of venous thrombosis: The MEGA case‐control study
por: Rietveld, Inge M., et al.
Publicado: (2018)

Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐ and low‐dose rivaroxaban with aspirin
por: Boonyawat, Kochawan, et al.
Publicado: (2021)

Targeted proteomics for evaluating risk of venous thrombosis following traumatic lower‐leg injury or knee arthroscopy
por: Mohammed, Yassene, et al.
Publicado: (2022)

Post‐thrombotic syndrome after upper extremity deep vein thrombosis: An international Delphi consensus study
por: de Kleijn, Robert J. C. M. F., et al.
Publicado: (2022)

Self‐reported therapy adherence and predictors for nonadherence in patients who switched from vitamin K antagonists to direct oral anticoagulants
por: Toorop, Myrthe M. A., et al.
Publicado: (2020)

Pulmonary embolism at autopsy in cancer patients
por: Gimbel, Inge A., et al.
Publicado: (2021)

Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study
por: Zielinski, Gilda Denise, et al.
Publicado: (2019)

Novel inhibitor ZED3197 as potential drug candidate in anticoagulation targeting coagulation FXIIIa (F13a)
por: Pasternack, Ralf, et al.
Publicado: (2019)

Associations of coagulation factor X and XI with incident acute coronary syndrome and stroke: A nested case‐control study
por: Chen, Huiting, et al.
Publicado: (2021)

Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban
por: Bosch, Floris T. M., et al.
Publicado: (2021)

First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men
por: Nowotny, Bettina, et al.
Publicado: (2022)

Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma
por: Kaptein, Fleur H. J., et al.
Publicado: (2022)

The impact of body weight on rivaroxaban pharmacokinetics
por: Barsam, Sarah J., et al.
Publicado: (2017)

Safety and effectiveness of apixaban compared to warfarin in dialysis patients
por: Reed, Daniel, et al.
Publicado: (2018)

Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial
por: Orsi, Fernanda A., et al.
Publicado: (2019)

Rivaroxaban vs placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer
por: Becattini, Cecilia, et al.
Publicado: (2022)

Coagulation factors II, V, VII, IX, X and XI and mortality – a cohort study
por: Yap, Eng Soo, et al.
Publicado: (2023)

Cryo-EM structure of coagulation factor V short
por: Mohammed, Bassem M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q7hskddokeem56e75drdjr4ima